Reliis is a Western Australian drug-reformulating company, seeking to make meaningful differences to patient care globally. Currently, Reliis has a product pipeline consisting of several high-priority drugs and a medical device. Reliis has a commitment to advancing healthcare through innovation and addressing critical challenges in patient treatment and care.
|
NEWS: Tagged in Patrys acquire Perth biotech for delirium drug | 13 Mar 2026 |
|
NEWS: Tagged in Patrys makes bold clinical-stage move with acquisition of WA private company Reliis, adding high-value delirium asset to ignite next phase of growth | 26 Nov 2025 |
|
NEWS: Tagged in Bridging WA's Innovation to Commercialisation Gap | 09 Sep 2024 |
|
NEWS: Tagged in WA Biotech Boom: Reliis and NovaCina's Perfect Partnership | 29 Jul 2024 |
|
NEWS: Tagged in Bowden takes top spot at 40u40 awards | 03 May 2024 |
|
NEWS: Tagged in Gold detector wins innovation top prize | 11 Mar 2024 |
|
NEW ROLE: Kerryn Garrett, Chief Scientific Officer | 07 Mar 2024 |
|
NEW ROLE: Jeremy Taylor, Non-Executive Director | 07 Mar 2024 |
|
NEW ROLE: Leanne Kite, Executive Director and Chief Financial Officer | 07 Mar 2024 |
|
NEW ROLE: Dino Cercarelli, Managing Director | 07 Mar 2024 |
